在患有过敏性喘的儿童中使用SQ House Dust Mite 语言下免疫疗法片:一项随机的III期试验
Graham Roberts1,2,3, Jocelyne Just4,5,6, Hendrik Nolte7
1The David Hide Asthma and Allergy Centre, St Mary's Hospital, Newport, Isle of Wight, UK.
Allergy
|October 9, 2025
概括
针对儿童的室内灰尘 (HDM) 过敏性喘的语言下免疫疗法 (SLIT) 平板显示出良好的耐受性,但由于恶化率低于预期,未达到主要终点. 需要进一步的研究来证实在儿科患者群体中的疗效.
科学领域:
- 过敏和免疫学 过敏和免疫学
- 儿科肺病学 儿科肺病学
- 临床试验 临床试验
背景情况:
- 家庭灰尘虫 (HDM) 敏感性是儿科过敏喘的一个关键因素.
- 在成年人中,HDM过敏原免疫疗法是有效的,但儿科数据有限.
- 这项研究研究了SQ HDM语言下免疫疗法 (SLIT) 平板在5-17岁的患有HDM过敏喘的儿童中.
研究的目的:
- 评估SQ HDM SLIT片在患有不充分控制的HDM过敏喘的儿童中的疗效和安全性.
- 作为主要终点,评估临床相关喘恶化年率.
- 为了监测与SQ HDM SLIT片治疗相关的不良事件.
主要方法:
- 第三阶段,随机,双盲,安慰剂对照试验,涉及533名儿童.
- 在24-30个月内每天服用SQ HDM SLIT片或安慰剂.
- 儿童有喘恶化病史,尽管接受了标准治疗.
主要成果:
- 喘恶化的比率为0.89 (95% CI:0.60,1.31),有利于SLIT片,但没有建立优势.
- 大多数与治疗相关的不良事件是轻度/中度,停药率低 (<2%).
- 常见的副作用包括口腔和喉刺激;没有观察到喘事件增加,过敏反应或上腺素使用.
结论:
- 该研究的主要终点未实现,原因是喘恶化率明显低于预期,部分受到COVID-19大流行的影响.
- 在SQ HDM SLIT片中,在被研究的儿科患者群体中表现出良好的耐受性.
- 虽然在统计学上并不优越,但研究结果表明,在治疗儿科HDM过敏喘时,有潜在的益处和安全性.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
01:30Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
01:24Antiasthma Drugs: Methylxanthines
1.6K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.6K
01:26Asthma-II: Pathophysiology and Classification
4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K